GSK: reports positive HIV drug trial results.
(CercleFinance.com) - ViiV Healthcare, the specialist HIV company majority owned by GSK, said a phase II study showed comparable viral suppression rates for its two-drug regimen compared with a three-drug regimen in patients with HIV.
96-week data showed injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) as a two-drug treatment achieved viral suppression rates that were comparable to the rate observed in patients with HIV-1 infection who had already achieved viral suppression with a three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors.
This outcome could remove the daily dosing burden for patients, GSK said.
The results published in The Lancet are being presented at the International AIDS Society Meeting in Paris.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
96-week data showed injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) as a two-drug treatment achieved viral suppression rates that were comparable to the rate observed in patients with HIV-1 infection who had already achieved viral suppression with a three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors.
This outcome could remove the daily dosing burden for patients, GSK said.
The results published in The Lancet are being presented at the International AIDS Society Meeting in Paris.
Copyright (c) 2017 CercleFinance.com. All rights reserved.